Amgen to Report Earnings Ahead of Schedule

Amgen Inc. said it will report second-quarter earnings Monday, about 10 days ahead of schedule, citing “unusual” trading in its stock in the last week. Amgen shares have soared more than 13% this week in heavier-than-usual trading amid expectations that the biotechnology company’s results will exceed forecasts, buoyed by strong sales of its top-selling drug, the anemia treatment Epogen. Thousand Oaks-based Amgen is expected to earn 46 cents a share in the second quarter, the average forecast of analysts surveyed by First Call Corp. Amgen shares rose $3.69 to close at $69.31 on Nasdaq.